Cimarex Energy Co. (NYSE: XEC)
concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Cabot Oil & Gas Corporation. Under the terms of the agreement, Cimarex Energy shareholders will receive 4.0146 shares of Cabot Oil common stock for each share of Cimarex Energy common stock owned.
If you are a Cimarex Energy shareholder,
.
Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
Shareholders are encouraged to contact the firm
free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected].
Cimarex Energy Co. (NYSE:XEC)
concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Cabot Oil & Gas Corporation. Under the terms of the agreement, Cimarex Energy shareholders will receive 4.0146 shares of Cabot Oil common stock for each share of Cimarex Energy common stock owned.
If you are a Cimarex Energy shareholder,
.
Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
Shareholders are encouraged to contact the firm
free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected].
Share this article
Share this article
NEW YORK, July 3, 2021 /PRNewswire/ Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated
Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating
Acasti Pharma, Inc. ( ACST or the Company ) (
) relating to its proposed merger with Grace Therapeutics, Inc. ACST shareholders are expected to own approximately 55% of the combined company.
The investigation focuses on whether Acasti Pharma, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.
NEW YORK, July 3, 2021 /PRNewswire/ Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated
Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating
Acasti Pharma, Inc. (“ACST” or the “Company”) (
) relating to its proposed merger with Grace Therapeutics, Inc. ACST shareholders are expected to own approximately 55% of the combined company.
The investigation focuses on whether Acasti Pharma, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.
Message :
Required fields
NEW YORK, July 3, 2021 /PRNewswire/ Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated
Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating
Acasti Pharma, Inc. ( ACST or the Company ) (
) relating to its proposed merger with Grace Therapeutics, Inc. ACST shareholders are expected to own approximately 55% of the combined company.
The investigation focuses on whether Acasti Pharma, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.